CAR T-Cell Therapy May ‘ Change the Paradigm of Treating Mesothelioma ’

Thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering (MSK) Cancer Center believes customized gene therapy will soon change the way pleural mesothelioma is treated. Adusumilli, director of the Mesothelioma Program at MSK, has worked for a decade on developing tumor immunology for thoracic malignancies. He is currently the principal investigator of a phase I clinical trial involving specially prepared immune cells — chimeric antigen receptor (CAR) T cells — that have shown impressive efficacy with mesothelioma. "I think this is going to change the paradigm of treating mesothelioma," Adusumilli told Asbestos.com. "We are seeing results now. We are going in the right direction." Adusumilli presented a preliminary report of his study at the 2018 American ...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zSLkfb